The global atazanavir market is anticipated to grow at a significant CAGR during the forecast period (2022-2028). Atazanavir is used in combination with other drugs to treat HIV infection in adults and children at least 3 months old and weighing 22 lb (10 kg). The development of a potential treatment for HIV disease is commonly known as DA drug development. Many companies are investing heavily in finding a cure and preventing HIV disease permanently. Therefore, the market for this drug development seems to be an excellent investment opportunity. The HIV patients are the key end-users of these drugs. Therefore, the districts with high rates of young people or adults will attract a greater need for these drugs.
(Get 15% Discount on Buying this Report)
A full report of Global Atazazavir Market is available at: https://orionmarketreports.com/atazazavir-market/93079/
In June 2021 more than 30 antiretroviral drugs in eight classes of FDA equipment were approved to treat HIV infection. These eight classes include drugs such as nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors (PIs), integrase strand transfer inhibitors (INSTIs), fusion inhibitor, CDCR5 antagonist CDR5 lymphocyte post-attachment inhibitor, and gp120 attachment inhibitor.
Atazanavir is an FDA-approved treatment for HIV-1 infection, combined with other antiretrovirals, in patients 3 months or older, weighing 5 pounds or more. It is in the protease inhibitor class of HIV-1 drugs. This work will highlight indicators, modalities, management, side effects, contraindications, and atazanavir monitoring appropriate for health team members in the management of HIV / AIDS patients. The rising number of HIV patients is a key factor creating demand for the atazanavir drug market.
The market players such as Cipla Inc., GlaxoSmithKline plc, Sanofi SA, and Pfizer Inc. among are contributing significantly to the growth of the market by the adoption of various strategies including mergers & acquisitions, geographical expansion, partnerships and collaborations, and new product launches, to stay competitive in the market. For instance, in August 2019, Cipla Ltd.had received final approval for its abbreviated application of atazanavir Caps 100mg, 150mg, 200mg, 300mg to the US FDA. Cipla’s Atazanavir Caps 100mg, 150mg, 200mg, 300mg is an AB equivalent version of the standard treatment of Bristol-Myers Squibb Pharma Company’s, atazanavir and it is a protease inhibitor that has been shown to be combined with other antiretrovirals in the treatment of HIV-1 infection in patients younger than 6 years and older who weigh at least 15 kg.
Market Coverage
- The market number available for – 2021-2028
- Base year- 2021
- Forecast period- 2022-2028
- Segment Covered-
- By Type
- By Application
- Regions Covered-
- North America
- Europe
- Asia-Pacific
- Rest of the World
- Competitive Landscape-Teva Pharmaceutical Industries Ltd., Cipla Inc., GlaxoSmithKline plc, Sanofi SA, and Pfizer Inc.,among others.
Key questions addressed by the report
- What is the market growth rate?
- Which segment and region dominate the market in the base year?
- Which segment and region will project the fastest growth in the market?
- How has COVID-19 impacted the market?
- Deviation from the pre-COVID-19 forecast
- Most affected region and segment
- Who is the leader in the market?
- How players are addressing challenges to sustain growth?
- Where is the investment opportunity?
Global Atazazavir Market Report by Segment
By Type
- 150 mg Capsule
- 200 mg Capsule
- 300 mg Capsule
- 50 mg Oral Powder
By Application
- Adults
- Children 3 months of age and older
About Us:
Orion Market Reports (OMR) endeavors to provide an exclusive blend of qualitative and quantitative market research reports to clients across the globe. Our organization helps both multinational and domestic enterprises to bolster their business by providing in-depth market insights and the most reliable future market trends. Our reports address all the major aspects of the markets providing insights and market outlook to global clients.
Media Contact:
Company Name: Orion Market Reports
Contact Person: Mr. Anurag Tiwari
Email: info@orionmarketreports.com
Contact no: +91 780-304-0404
